WallStSmart

Medtronic PLC (MDT)vsNexalin Technology Inc. (NXL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 22611255% more annual revenue ($35.48B vs $156,930). MDT leads profitability with a 13.0% profit margin vs 0.0%. MDT earns a higher WallStSmart Score of 56/100 (C).

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0

NXL

Avoid

20

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Intrinsic value data unavailable for NXL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

NXL1 strengths · Avg: 8.0/10
Price/BookValuation
1.5x8/10

Reasonable price relative to book value

Areas to Watch

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

NXL4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.57M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-1.8%2/10

ROE of -1.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bull Case : NXL

The strongest argument for NXL centers on Price/Book.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Bear Case : NXL

The primary concerns for NXL are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

NXL carries more volatility with a beta of 4.10 — expect wider price swings.

MDT is growing revenue faster at 8.7% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDT scores higher overall (56/100 vs 20/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Nexalin Technology Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Nexalin Technology Inc. is a pioneering player in the medical technology sector, specializing in advanced therapies for neurological and psychiatric disorders. The company develops proprietary transcranial electrical stimulation devices that offer non-invasive treatment options for conditions such as anxiety, depression, and substance addiction. With a strong emphasis on cutting-edge research and mental health improvement, Nexalin is positioned to capitalize on the growing demand for innovative healthcare solutions. Its strategic focus on enhancing patient outcomes through technological advancements highlights its potential for substantial growth in the rapidly evolving digital health landscape.

Want to dig deeper into these stocks?